FRANÇAIS TABLE OF CONTENTS PREVIOUS PAGE NEXT PAGE RELATED LINKS SUBSCRIBE

TreatmentUpdate 173

Volume 21 Issue 4

2009 May/June

I ANTI-HIV AGENTS: B. Raltegravir (Isentress)

Raltegravir works by interfering with a viral enzyme called integrase. It is the first integrase inhibitor available for the treatment of HIV infection. Initially developed for use by treatment-experienced patients, once raltegravir had shown that it was a very effective part of combination therapy in this group, it was also developed for use as first-line therapy in people who have never used anti-HIV drugs. Raltegravir is taken twice daily with or without food.

In this issue of TreatmentUpdate, we review results from clinical trials in which raltegravir has been used as follows:

• results after two years of using raltegravir
• interim results from a trial of raltegravir in first-line therapy
• a review of cases of cancer seen in trials of raltegravir

Created on: 2009 June 9

Author: Hosein SR

Related links

CATIE-News

What's New?

CATIE Publications

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner who is knowledgeable about HIV-related illness and the treatments in question. MORE

Privacy | Permission to reproduce | Funders

Production of this Web site has been made possible through a financial contribution from the Public Health Agency of Canada.